Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

T. H. Jafar, C. H. Schmid, M. Landa, I. Giatras, R. Toto, G. Remuzzi, G. Maschio, B. M. Brenner, A. Kamper, P. Zucchelli, G. Becker, A. Himmelmann, K. Bannister, P. Landais, S. Shahinfar, P. E. De Jong, D. De Zeeuw, J. Lau, A. S. Levey

Research output: Contribution to journalArticle

796 Citations (Scopus)

Abstract

Purpose: To examine the efficacy of ACE inhibitors for treatment of nondiabetic renal disease. Data Sources: 11 randomized, controlled trials comparing the efficacy of antihypertensive regimens including ACE inhibitors to the efficacy of regimens without ACE inhibitors in predominantly nondiabetic renal disease. Study Selection: Studies were identified by searching the MEDLINE database for English-language studies evaluating the effects of ACE inhibitors on renal disease in humans between May 1977 (when ACE inhibitors were approved for trials in humans) and September 1997. Data Extraction: Data on 1860 nondiabetic patients were analyzed. Data Synthesis: Mean duration of follow-up was 2.2 years. Patients in the ACE inhibitor group had a greater mean decrease in systolic and diastolic blood pressure (4.5 mm Hg [95% Cl, 3.0 to 6.1 mm Hg]) and 2.3 mm Hg [Cl, 1.4 to 3.2 mm Hg], respectively) and urinary protein excretion (0.46 g/d [Cl, 0.33 to 0.59 g/d]). After adjustment for patient and study characteristics at baseline and changes in systolic blood pressure and urinary protein excretion during follow-up, relative risks in the ACE inhibitor group were 0.69 (Cl, 0.51 to 0.94) for end-stage renal disease and 0.70 (Cl, 0.55 to 0.88) for the combined outcome of doubling of the baseline serum creatinine concentration or end-stage renal disease. Patients with greater urinary protein excretion at baseline benefited more from ACE inhibitor therapy (P = 0.03 and P = 0.001, respectively), but the data were inconclusive as to whether the benefit extended to patients with baseline urinary protein excretion less than 0.5 g/d. Conclusion: Antihypertensive regimens that include ACE inhibitors are more effective than regimens without ACE inhibitors in slowing the progression of nondiabetic renal disease. The beneficial effect of ACE inhibitors is mediated by factors in addition to decreasing blood pressure and urinary protein excretion and is greater in patients with proteinuria. Angiotensin-converting inhibitors are indicated for treatment of nondiabetic patients with chronic renal disease and proteinuria and, possibly, those without proteinuria.

Original languageEnglish (US)
Pages (from-to)73-87
Number of pages15
JournalAnnals of Internal Medicine
Volume135
Issue number2
StatePublished - Jul 17 2001

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Meta-Analysis
Kidney
Blood Pressure
Proteinuria
Proteins
Antihypertensive Agents
Chronic Kidney Failure
Information Storage and Retrieval
Angiotensins
Chronic Renal Insufficiency
MEDLINE
Creatinine
Language
Therapeutics
Randomized Controlled Trials
Databases

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., ... Levey, A. S. (2001). Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Annals of Internal Medicine, 135(2), 73-87.

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. / Jafar, T. H.; Schmid, C. H.; Landa, M.; Giatras, I.; Toto, R.; Remuzzi, G.; Maschio, G.; Brenner, B. M.; Kamper, A.; Zucchelli, P.; Becker, G.; Himmelmann, A.; Bannister, K.; Landais, P.; Shahinfar, S.; De Jong, P. E.; De Zeeuw, D.; Lau, J.; Levey, A. S.

In: Annals of Internal Medicine, Vol. 135, No. 2, 17.07.2001, p. 73-87.

Research output: Contribution to journalArticle

Jafar, TH, Schmid, CH, Landa, M, Giatras, I, Toto, R, Remuzzi, G, Maschio, G, Brenner, BM, Kamper, A, Zucchelli, P, Becker, G, Himmelmann, A, Bannister, K, Landais, P, Shahinfar, S, De Jong, PE, De Zeeuw, D, Lau, J & Levey, AS 2001, 'Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data', Annals of Internal Medicine, vol. 135, no. 2, pp. 73-87.
Jafar, T. H. ; Schmid, C. H. ; Landa, M. ; Giatras, I. ; Toto, R. ; Remuzzi, G. ; Maschio, G. ; Brenner, B. M. ; Kamper, A. ; Zucchelli, P. ; Becker, G. ; Himmelmann, A. ; Bannister, K. ; Landais, P. ; Shahinfar, S. ; De Jong, P. E. ; De Zeeuw, D. ; Lau, J. ; Levey, A. S. / Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. In: Annals of Internal Medicine. 2001 ; Vol. 135, No. 2. pp. 73-87.
@article{4e5ec9cd2eba41ce837dd835e85ca4e1,
title = "Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data",
abstract = "Purpose: To examine the efficacy of ACE inhibitors for treatment of nondiabetic renal disease. Data Sources: 11 randomized, controlled trials comparing the efficacy of antihypertensive regimens including ACE inhibitors to the efficacy of regimens without ACE inhibitors in predominantly nondiabetic renal disease. Study Selection: Studies were identified by searching the MEDLINE database for English-language studies evaluating the effects of ACE inhibitors on renal disease in humans between May 1977 (when ACE inhibitors were approved for trials in humans) and September 1997. Data Extraction: Data on 1860 nondiabetic patients were analyzed. Data Synthesis: Mean duration of follow-up was 2.2 years. Patients in the ACE inhibitor group had a greater mean decrease in systolic and diastolic blood pressure (4.5 mm Hg [95{\%} Cl, 3.0 to 6.1 mm Hg]) and 2.3 mm Hg [Cl, 1.4 to 3.2 mm Hg], respectively) and urinary protein excretion (0.46 g/d [Cl, 0.33 to 0.59 g/d]). After adjustment for patient and study characteristics at baseline and changes in systolic blood pressure and urinary protein excretion during follow-up, relative risks in the ACE inhibitor group were 0.69 (Cl, 0.51 to 0.94) for end-stage renal disease and 0.70 (Cl, 0.55 to 0.88) for the combined outcome of doubling of the baseline serum creatinine concentration or end-stage renal disease. Patients with greater urinary protein excretion at baseline benefited more from ACE inhibitor therapy (P = 0.03 and P = 0.001, respectively), but the data were inconclusive as to whether the benefit extended to patients with baseline urinary protein excretion less than 0.5 g/d. Conclusion: Antihypertensive regimens that include ACE inhibitors are more effective than regimens without ACE inhibitors in slowing the progression of nondiabetic renal disease. The beneficial effect of ACE inhibitors is mediated by factors in addition to decreasing blood pressure and urinary protein excretion and is greater in patients with proteinuria. Angiotensin-converting inhibitors are indicated for treatment of nondiabetic patients with chronic renal disease and proteinuria and, possibly, those without proteinuria.",
author = "Jafar, {T. H.} and Schmid, {C. H.} and M. Landa and I. Giatras and R. Toto and G. Remuzzi and G. Maschio and Brenner, {B. M.} and A. Kamper and P. Zucchelli and G. Becker and A. Himmelmann and K. Bannister and P. Landais and S. Shahinfar and {De Jong}, {P. E.} and {De Zeeuw}, D. and J. Lau and Levey, {A. S.}",
year = "2001",
month = "7",
day = "17",
language = "English (US)",
volume = "135",
pages = "73--87",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "2",

}

TY - JOUR

T1 - Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

AU - Jafar, T. H.

AU - Schmid, C. H.

AU - Landa, M.

AU - Giatras, I.

AU - Toto, R.

AU - Remuzzi, G.

AU - Maschio, G.

AU - Brenner, B. M.

AU - Kamper, A.

AU - Zucchelli, P.

AU - Becker, G.

AU - Himmelmann, A.

AU - Bannister, K.

AU - Landais, P.

AU - Shahinfar, S.

AU - De Jong, P. E.

AU - De Zeeuw, D.

AU - Lau, J.

AU - Levey, A. S.

PY - 2001/7/17

Y1 - 2001/7/17

N2 - Purpose: To examine the efficacy of ACE inhibitors for treatment of nondiabetic renal disease. Data Sources: 11 randomized, controlled trials comparing the efficacy of antihypertensive regimens including ACE inhibitors to the efficacy of regimens without ACE inhibitors in predominantly nondiabetic renal disease. Study Selection: Studies were identified by searching the MEDLINE database for English-language studies evaluating the effects of ACE inhibitors on renal disease in humans between May 1977 (when ACE inhibitors were approved for trials in humans) and September 1997. Data Extraction: Data on 1860 nondiabetic patients were analyzed. Data Synthesis: Mean duration of follow-up was 2.2 years. Patients in the ACE inhibitor group had a greater mean decrease in systolic and diastolic blood pressure (4.5 mm Hg [95% Cl, 3.0 to 6.1 mm Hg]) and 2.3 mm Hg [Cl, 1.4 to 3.2 mm Hg], respectively) and urinary protein excretion (0.46 g/d [Cl, 0.33 to 0.59 g/d]). After adjustment for patient and study characteristics at baseline and changes in systolic blood pressure and urinary protein excretion during follow-up, relative risks in the ACE inhibitor group were 0.69 (Cl, 0.51 to 0.94) for end-stage renal disease and 0.70 (Cl, 0.55 to 0.88) for the combined outcome of doubling of the baseline serum creatinine concentration or end-stage renal disease. Patients with greater urinary protein excretion at baseline benefited more from ACE inhibitor therapy (P = 0.03 and P = 0.001, respectively), but the data were inconclusive as to whether the benefit extended to patients with baseline urinary protein excretion less than 0.5 g/d. Conclusion: Antihypertensive regimens that include ACE inhibitors are more effective than regimens without ACE inhibitors in slowing the progression of nondiabetic renal disease. The beneficial effect of ACE inhibitors is mediated by factors in addition to decreasing blood pressure and urinary protein excretion and is greater in patients with proteinuria. Angiotensin-converting inhibitors are indicated for treatment of nondiabetic patients with chronic renal disease and proteinuria and, possibly, those without proteinuria.

AB - Purpose: To examine the efficacy of ACE inhibitors for treatment of nondiabetic renal disease. Data Sources: 11 randomized, controlled trials comparing the efficacy of antihypertensive regimens including ACE inhibitors to the efficacy of regimens without ACE inhibitors in predominantly nondiabetic renal disease. Study Selection: Studies were identified by searching the MEDLINE database for English-language studies evaluating the effects of ACE inhibitors on renal disease in humans between May 1977 (when ACE inhibitors were approved for trials in humans) and September 1997. Data Extraction: Data on 1860 nondiabetic patients were analyzed. Data Synthesis: Mean duration of follow-up was 2.2 years. Patients in the ACE inhibitor group had a greater mean decrease in systolic and diastolic blood pressure (4.5 mm Hg [95% Cl, 3.0 to 6.1 mm Hg]) and 2.3 mm Hg [Cl, 1.4 to 3.2 mm Hg], respectively) and urinary protein excretion (0.46 g/d [Cl, 0.33 to 0.59 g/d]). After adjustment for patient and study characteristics at baseline and changes in systolic blood pressure and urinary protein excretion during follow-up, relative risks in the ACE inhibitor group were 0.69 (Cl, 0.51 to 0.94) for end-stage renal disease and 0.70 (Cl, 0.55 to 0.88) for the combined outcome of doubling of the baseline serum creatinine concentration or end-stage renal disease. Patients with greater urinary protein excretion at baseline benefited more from ACE inhibitor therapy (P = 0.03 and P = 0.001, respectively), but the data were inconclusive as to whether the benefit extended to patients with baseline urinary protein excretion less than 0.5 g/d. Conclusion: Antihypertensive regimens that include ACE inhibitors are more effective than regimens without ACE inhibitors in slowing the progression of nondiabetic renal disease. The beneficial effect of ACE inhibitors is mediated by factors in addition to decreasing blood pressure and urinary protein excretion and is greater in patients with proteinuria. Angiotensin-converting inhibitors are indicated for treatment of nondiabetic patients with chronic renal disease and proteinuria and, possibly, those without proteinuria.

UR - http://www.scopus.com/inward/record.url?scp=0035902622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035902622&partnerID=8YFLogxK

M3 - Article

VL - 135

SP - 73

EP - 87

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 2

ER -